Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06027749

Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With Remote EEG Monitoring System.

The goal of this clinical trial is to test Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days) in patients presenting with questionable seizure characterization. The main questions it aims to answer are: • Can more seizure events be recorded in fourteen (14) days than can be recorded in three (3) days? • Do treating clinicians find clinical value in extended fourteen (14) - twenty-eight (28) days of EEG? Participants will wear a portable EEG device (REMI) for fourteen (14) to twenty-eight (28) days in their home/community setting.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of South Florida, Tampa, Florida, United States

Loading trial locations.

About this study

This is a prospective study to quantify Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days). Patients presenting with questionable seizure characterization that are scheduling a conventional at home ambulatory EEG (Amb EEG) and who meet the study inclusion and exclusion criteria will be prescribed a REMI system.

The purpose of this study is to demonstrate that the REMI system is able to record EEG data that clinicians can use to identify ictal events over extended periods, and that extended clinical EEG data is valuable in the diagnosis and treatment of seizure related symptoms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients have a reported history of seizures (epileptic, non-epileptic, or unknown),
  • Have a minimum reported seizure rate of one every two weeks,
  • Are prescribed an ambulatory EEG study as part of routine care,
  • Is Male or Female between the ages of 18 and 70,
  • Can understand and sign written informed consent, or have a legal guardian provide consent,
  • The Patient (or Primary Caregiver) must be competent to follow all study procedures,
  • The Patient must be willing to use the System for a prolonged period (up to 30 days), for a minimum of 20 hours/day.

Exclusion criteria

  • Is sensitive or allergic to medical acrylics, silicones, or hydrogels,
  • Is enrolled in another investigational drug or device trial,
  • Is homeless or in a home without a power supply, or
  • Cannot read, speak, or understand English (and does not have a translator).

Treatment and study plan

Epitel's™ Remote EEG Monitoring System's (REMI™)

Device

Ambulatory electroencephalography (EEG) monitoring

Primary outcomes

  1. Ictal Events Identified in fourteen (14) days.

    Time frame: Fourteen (14) days

    Epileptiform seizure activity as identified by three independent board-certified epileptologists assessing data collected by REMI. The number of seizures identified in the first three days will be compared to the number of seizures identified during days one (1) to fourteen (14).

Secondary outcomes

  1. Extended Use

    Time frame: Twenty-eight (28) days

    Epileptiform seizure activity as identified by three independent board-certified epileptologists assessing data collected by REMI. The number of seizures identified in the first fourteen (14) days will be compared to the number of seizures identified during all twenty-eight (28) days.

Sponsors and collaborators

Lead sponsor

Epitel, Inc.

Industry

Registry information

Official study title

Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With REMI.

Acronym: REMI

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Sep 7, 2023
Registry last updated
Aug 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.